Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Centessa Pharmaceuticals (CNTA – Research ...

Spiromacrocyclic compounds acting as orexin OX2 receptor agonists have been described in an H. Lundbeck A/S patent and reported to be useful for the treatment of type 1 and type 2 narcolepsy.

Orexin antagonists, meanwhile – such as Eisai's Dayvigo (lemborexant), Merck & Co's Belsomra (suvorexant) and Idorsia's recently filed daridorexant – have proved effective as treatments for ...

NLS Pharmaceuticals stock is moving higher on Monday after the company announced it filed a F-4 registration statement with ...

Nxera Pharma, the Japan-based company with an R&D facility on Granta Park, has launched insomnia treatment QUVIVIQ ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Centessa Pharmaceuticals ( (CNTA) ) has provided an update.

Recently, we announced details around our preclinical program to evaluate two candidates, AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs designed to target both orexin-1 and orexin-2 ...

The firm's stance is influenced by the potential of ALKS-2680, an orexin 2 receptor (OX2R) agonist currently in development for the treatment of sleep/wake disorders. A leading sleep expert ...